Neel A. Doshi, MD (@NeelDoshiMD) header
Neel A. Doshi, MD (@NeelDoshiMD) profile picture

M.D. | Resident Physician, Internal Medicine🇺🇸 @InfirmaryHealth | Aspiring Cardiologist🫀| Cinema Buff🍿| Marvel Fan | Tennis🎾| #CardioX #MedTwitter

Mobile, USA
Joined November 2011
Photo by Neel A. Doshi, MD (@NeelDoshiMD)Photo by Neel A. Doshi, MD (@NeelDoshiMD)Photo by Neel A. Doshi, MD (@NeelDoshiMD)Photo by Neel A. Doshi, MD (@NeelDoshiMD)Photo by Neel A. Doshi, MD (@NeelDoshiMD)Photo by Neel A. Doshi, MD (@NeelDoshiMD)Photo by Neel A. Doshi, MD (@NeelDoshiMD)Photo by Neel A. Doshi, MD (@NeelDoshiMD)Photo by Neel A. Doshi, MD (@NeelDoshiMD)Photo by Neel A. Doshi, MD (@NeelDoshiMD)
Neel A. Doshi, MD retweeted
#Cangrelor versus crushed #ticagrelor in #AMI complicated by cardiogenic shock (#DAPT-SHOCK-AMI) DAPT-SHOCK-AMI: First RCT comparing #P2Y12i strategies in AMI-CS. 📍Platelet inhibition: 100% vs 22% (p<0.0001), favoring cangrelor. 📍30-day clinical outcomes: 38% vs 41%; non-inferiority not demonstrated (P=0.13). 📍Major bleeding: 6% vs 5%. sciencedirect.com/science/ar… @TheLancet
2
23
81
6,006
Neel A. Doshi, MD retweeted
Treatment of Essential Hypertension (Adults) Step 1 ◻️ Age <55 years: Start an ACE inhibitor (ACEi) or ARB (ARB if ACEi is not tolerated). ◻️ Age ≥55 years or Black African/Black Caribbean ethnicity: Start a calcium channel blocker (CCB). Step 2 ◼️ACEi/ARB + CCB ◼️ If a CCB is not tolerated, use a thiazide-like diuretic instead. Step 3 ◻️ ACEi/ARB + CCB + thiazide-like diuretic Step 4 (Resistant Hypertension) ◻️ If serum potassium is ≤4.5 mmol/L: Add low-dose spironolactone. ◻️ If serum potassium is >4.5 mmol/L: Consider an alpha-blocker or beta-blocker, or seek specialist advice. Key point: Use either an ACE inhibitor or an ARB, never both together. Reference: NICE Guideline NG136: Hypertension in adults: diagnosis and management (updated February 2026).
5
125
6
470
28,520
Neel A. Doshi, MD retweeted
🫀 CardioNugget™: ΔCT-FFR — the drop matters CT-FFR tells you the pressure distal to a lesion. ΔCT-FFR tells you how much pressure that specific lesion costs. 📉 ΔCT-FFR = FFRCT proximal − FFRCT distal Example: 0.92 → stenosis → 0.74 → ΔCT-FFR = 0.18 Why care? A larger focal drop suggests the stenosis itself is driving the physiologic impairment—not just diffuse disease. 🎯 ΔCT-FFR >0.13 has been associated with greater likelihood of early revascularization. Think: FFRCT = “Is flow impaired downstream?” ΔCT-FFR = “How much is THIS lesion responsible?” #CardioNugget #CardioTwitter #CCTA #FFRCT #Cardiology #MedEd
7
31
1,773
Neel A. Doshi, MD retweeted
🚨 BREAKING: Claude has a feature called Reading & Learning Mode. You can use it to learn anything faster than 99% of people. Here are 5 prompts to access it:
45
438
7
4,106
546,047
Neel A. Doshi, MD retweeted
If you want to be a winner and want to stay a winner, engrave this in your mind. You can never stop. No matter what you achieve, you keep going. Make winning a habit, and your work the reward.
74
227
6
2,881
78,334
Neel A. Doshi, MD retweeted
It was the smartest of times It was the dumbest of times
7,964
14,797
1,604
163,949
8,358,970
Neel A. Doshi, MD retweeted
🚨Check out our review 📃 on the evolution of #STEMI care from culprit-only to complete revasc & the emerging role of preventive #PCI of high risk NCLs!🫀@ccijournal @MayoClinic @MayoCVFellows #cardiotwitter #IC #ACCFIT #MedTwitter @MayoClinicCV 👇 onlinelibrary.wiley.com/doi/…
3
21
71
4,778
Neel A. Doshi, MD retweeted
We made it! ❤️
669
7,811
227
103,439
4,599,630
Neel A. Doshi, MD retweeted
Robert Pattinson is James Bond
24,841
213,951
84,919
1,384,246
76,031,975
Neel A. Doshi, MD retweeted
NEVERRRRRR underestimate how much God is protecting you from things you don’t even know about.
165
3,037
92
34,123
482,925
Neel A. Doshi, MD retweeted
The cheat code to life is genuinely believing you're going to make it even when absolutely nothing is working.
272
7,893
258
57,550
939,442
Neel A. Doshi, MD retweeted
Original Article: Prasugrel versus Ticagrelor in Acute Coronary Syndromes (SWITCH-SWEDEHEART trial) nej.md/4wGVCZd Editorial: The Emerging Role of Treatment Policy Implementation Trials in Acute Coronary Syndrome nej.md/45FxURZ #ESCCongress #Cardiology
8
38
159
26,715
Neel A. Doshi, MD retweeted
👉Statin + Ezetimibe: Better Together More real-world evidence supporting combination lipid-lowering therapy. New study in European Heart Journal – Cardiovascular Pharmacotherapy. 1️⃣ 309,371 patients with dyslipidemia included in a nationwide Korean target trial emulation. 2️⃣ 13% lower risk of myocardial infarction with statin + ezetimibe versus statin monotherapy in early cardiovascular–kidney–metabolic (CKM) risk (HR 0.87; 95% CI 0.81–0.95). 3️⃣ 12% lower risk in patients with more advanced CKM risk (HR 0.88; 95% CI 0.79–0.98). 4️⃣ Greater LDL-C reductions with combination therapy, particularly relevant when comparing moderate-intensity statin regimens. 5️⃣ Higher prescription coverage with fixed-dose combination therapy, suggesting a potential advantage for treatment persistence. ☝️ The message is clear: targeting complementary cholesterol pathways may improve cardiovascular prevention. ☝️ Why wait to intensify treatment when we can achieve greater LDL-C reductions from the start? 🔗 🔓doi.org/10.1093/ehjcvp/pvag0… @society_eas
15
74
3
235
18,506
Neel A. Doshi, MD retweeted
drive.google.com/file/d/1S4N… Friends planning on studying for the cardiac echo boards, this is my study Anki deck that I made while studying, based off the Klein 3rd edition material. It covers 90+% of the material. Hope you find it useful:) #echoboards #cardiotwitter
1
17
107
7,826
Neel A. Doshi, MD retweeted
I’m in love with this sentence: “An inch of movement is better than a mile of intentions.”
116
4,462
93
31,413
560,544
Neel A. Doshi, MD retweeted
👉 MUST READ; A landmark EAS Statement in the post-Lp(a)HORIZON era in @ATHjournal ☝️The European Atherosclerosis Society @society_eas delivers a timely, evidence-based message following the neutral results of Lp(a)HORIZON. 1️⃣ 78% Lp(a) reduction ≠ cardiovascular benefit. We must distinguish a causal risk factor from a validated therapeutic target. 2️⃣ Lp(a) remains a major cardiovascular risk factor. Measure it at least once in every adult. Family screening remains essential. 3️⃣ LDL-C lowering is our strongest actionable strategy. Intensive control of LDL-C and other risk factors can mitigate Lp(a)-associated risk. 4️⃣ Timing may be everything. Can a few years of treatment reverse decades of cumulative atherogenic exposure? 5️⃣ The science is far from over. Ongoing RCTs with different Lp(a)-lowering agents are essential. ☝️My key takeaway: A negative trial should change our assumptions, not replace scientific evidence with speculation. ☝️ Measure Lp(a). Lower LDL-C. Control global risk. Keep testing hypotheses with RCTs. 🔗 atherosclerosis-journal.com/… @BNordestgaard @ProfKausikRay @MeralKayikcoglu @KronenbergLab @j_rvl @SamiaMoraMD
10
34
8
114
10,111
Neel A. Doshi, MD retweeted
In case you missed it, here are all late breaking clinical trial results from #ScientificSessions26.
3
51
142
9,951
Neel A. Doshi, MD retweeted
In patients with suspected acute coronary syndrome without myocardial infarction, routine CT coronary angiography did not result in a lower incidence of myocardial infarction or death from a cardiac cause than standard care. Full TARGET-CTCA trial results and Research Summary: nej.md/4wH7Yk7 #ESCCongress
6
46
3
191
29,660
Neel A. Doshi, MD retweeted
never fucking quit. you have no idea how different your life could look in 6 months.
262
3,466
126
44,761
1,001,782
Neel A. Doshi, MD retweeted
Presented at #ScientificSessions26: In patients with atrioventricular block, left bundle-branch pacing resulted in a lower incidence of a composite of death, hospitalization for heart failure, or pacing-induced cardiomyopathy than right ventricular pacing. Full OptimPacing trial results: nej.md/4favsI9 @AHAScience
8
147
19
391
68,964